|
|
08-02-2016, 03:44 PM
|
#21
|
Recycles dryer sheets
Join Date: Apr 2013
Posts: 252
|
Fermion, I have short term traded IBB, did you ever consider an index option, of course less individual stock risk brings more damped highs and lows but the sector moves plenty for me. I started in the sector using FIDOs FBIOX, and still have it, feeling trapped to avoid the tax hit to realize gains since its in my after tax account.
Sent from my iPad using Early Retirement Forum
|
|
|
|
Join the #1 Early Retirement and Financial Independence Forum Today - It's Totally Free!
Are you planning to be financially independent as early as possible so you can live life on your own terms? Discuss successful investing strategies, asset allocation models, tax strategies and other related topics in our online forum community. Our members range from young folks just starting their journey to financial independence, military retirees and even multimillionaires. No matter where you fit in you'll find that Early-Retirement.org is a great community to join. Best of all it's totally FREE!
You are currently viewing our boards as a guest so you have limited access to our community. Please take the time to register and you will gain a lot of great new features including; the ability to participate in discussions, network with our members, see fewer ads, upload photographs, create a retirement blog, send private messages and so much, much more!
|
08-02-2016, 04:27 PM
|
#22
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Yes I have traded IBB in the past. It is not a bad way to go, but it doesn't remove a ton of risk because just a few companies make up the lion's share of the holdings.
On a side note, Gilead dropped back under $80 but I was driving in a no cell coverage zone. Maybe a further slide tomorrow and I rebuy 1000 shares at $79.
|
|
|
08-04-2016, 07:38 AM
|
#23
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
I was driving again yesterday and so had a limit buy for 500 Gilead at 79.50 and 500 at 78. The first filled so I am back to 1500 shares. Looking to sell 500 today at 81.
Endocyte reports today and maybe we will get some update on why the CEO left and how the trials are going. Stock is trading below cash on hand so not expecting much here.
|
|
|
08-04-2016, 09:36 AM
|
#24
|
Thinks s/he gets paid by the post
Join Date: Apr 2013
Location: Gosport, IN
Posts: 1,213
|
bought 500 shares of GILD at $80 today
|
|
|
08-10-2016, 01:40 PM
|
#25
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Bought 500 Gilead today at 78.80 bringing me back to 2000.
$960 dividend Sept 14
|
|
|
08-11-2016, 07:22 AM
|
#26
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
One interesting thesis on Gilead is that they spin off the Hep C business, which has great profits but declining growth, and keep the core HIV plus the pipeline (NASH, etc.).
The Hep C business is probably worth $40B to $50B even with the declining revenues. The HIV drugs had a growth of 17%, but because of the decline in new HCV business, they had an overall decline in YoY revenue. If they dump the HCV and bring the market cap down to about 60B with $15B revenue from HIV and 17% growth, the stock will sport a PE much greater than the current 7.
Just one of the many ways the current $79 share price could make you a ton of money.
|
|
|
08-12-2016, 05:12 PM
|
#27
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Epclusa, Gilead's new pan-genotypic single pill cure for Hep C had a 27.6% week over week gain in new prescriptions. While I am sure this is cannibalizing Harvoni and Sovaldi sales, it probably means they are holding their own in market share (around 90%).
Should be a pretty solid bottom here around $79 unless the whole market just tanks before the election. I wish I had a higher net worth so I could justify more than 2000 shares but that is already a tad high for one stock.
|
|
|
08-15-2016, 10:00 AM
|
#28
|
gone traveling
Join Date: Sep 2003
Location: DFW
Posts: 7,586
|
I just have a small stake in IBB. Many of these companies just have research going for them and no real earnings, so it probably takes more in the way of scientific knowledge and research to pick and choose individual companies that may pay off, so I'll leave that to the experts.
|
|
|
08-15-2016, 10:16 AM
|
#29
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Actually the IBB has a large portion of biotech which are quite profitable. It is a good index to hold if you are not picking and choosing.
|
|
|
08-17-2016, 08:51 AM
|
#30
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Sold 500 Gilead just now at $80.20 purchased at $78.80
Yes this is picking up pennies in front of a steam roller but I can't just sit back and let it ebb and flow a dollar a week without doing something productive.
Have 1500 shares now, will buy back 500 again under $79. Sigh.
One day they will figure out how to make this company shine.
|
|
|
08-18-2016, 08:04 AM
|
#31
|
Thinks s/he gets paid by the post
Join Date: Apr 2013
Location: Gosport, IN
Posts: 1,213
|
|
|
|
08-18-2016, 08:11 AM
|
#32
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Survive seems a little drastic considering they have 24B in cash and are making about $7B+ a year on the growing HIV segment alone.
Still, the split could mean an instant 20% gain in the share price which I and others on here would not complain about. I don't know if management would do it.
|
|
|
08-18-2016, 08:41 AM
|
#33
|
Thinks s/he gets paid by the post
Join Date: Apr 2013
Location: Gosport, IN
Posts: 1,213
|
I have a sell order at 84.25 so would lose out on most of a 20% rise anyway!
|
|
|
08-19-2016, 05:01 AM
|
#34
|
Thinks s/he gets paid by the post
Join Date: Apr 2013
Location: Gosport, IN
Posts: 1,213
|
Pharmacy Benefit Managers limiting coverage of certain drugs for 2017?
from GoodRX blog
Which drugs are affected?
Caremark in particular is making some major changes for 2016, which fall under three general categories: “hyperinflation” drugs (drugs that have had recent drastic price increases), new biosimilar alternatives, and stricter restrictions on expensive cancer and hepatitis C medications.
Hyperinflation. Caremark has identified some drugs that have had huge price increases, and excluded a selection that have similar alternatives in the same class of medications. One example is Alcortin A, which saw a 30-fold price hike over the past three years.
Biosimilars. You may have heard news over the past year or so about “biosimilars”—basically, generic medications for some specialty or biologic medications like insulin. (For more background on biosimilars, see our post here.)
Notably, Caremark will no longer cover Lantus, one of the most popular insulin brands.
Caremark is the first provider to restrict brand name drugs like Neupogen or Lantus that have (or will have) biosimilars available next year. They are suggesting Zarxio in place of Neupogen, and Basaglar in place of Lantus.
Express Scripts, in contrast, haven’t restricted coverage for either Lantus or Neupogen yet, but are maintaining that they plan to reassess based on upcoming product launches over the next year.
Expensive specialty medications. Caremark is also breaking ground by being the first provider to restrict coverage on brand name cancer treatments.
They are also restricting coverage for all of the new hepatitis C treatments, allowing only Sovaldi and Harvoni.
Express Scripts has similar—but not overlapping—restrictions, limiting coverage to only Viekira Pak and the newly approved Technivie, both from manufacturer Gilead.
|
|
|
08-19-2016, 07:24 AM
|
#35
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Viekera Pak is not from Gilead. That is AbbVie's 6 pill per day competition drug to Gilead's Harvoni and now Epclusa (which treats all types and will for a while be the one to beat).
|
|
|
08-19-2016, 08:34 AM
|
#36
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
My Endocyte (ECYT) is getting some action today for some reason. Nearly at the full day volume just an hour into the market and the stock is at $3.34 when it was trading at $3.05.
I only have 5000 shares but it would be exciting to wake up and see a four digit number on the price (including cents of course!)
|
|
|
08-24-2016, 08:15 AM
|
#37
|
Thinks s/he gets paid by the post
Join Date: Apr 2013
Location: Gosport, IN
Posts: 1,213
|
|
|
|
08-25-2016, 03:50 PM
|
#38
|
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Join Date: Sep 2012
Location: Seattle
Posts: 5,991
|
Today I had a limit order for Gilead at $79.50 which hit, so back to 2000 shares.
I also bought back 3000 shares of Endocyte at 3.04 which I had sold for 3.30 Monday, so quite happy with that.
|
|
|
08-29-2016, 10:16 AM
|
#39
|
Thinks s/he gets paid by the post
Join Date: Apr 2013
Location: Gosport, IN
Posts: 1,213
|
GILD getting a little beat up today.
|
|
|
08-29-2016, 12:06 PM
|
#40
|
Moderator Emeritus
Join Date: Apr 2011
Location: Conroe, Texas
Posts: 18,593
|
Quote:
Originally Posted by wmc1000
GILD getting a little beat up today.
|
It's their turn in the barrel.
__________________
*********Go Astros!*********
|
|
|
|
|
Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
|
|
Thread Tools |
|
Display Modes |
Linear Mode
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
|
» Recent Threads
|
|
|
|
|
|
|
|
|
|
|
|
|
» Quick Links
|
|
|